TRV734
Jump to navigation
Jump to search
Identifiers | |
---|---|
| |
PubChem CID | |
Chemical and physical data | |
Formula | C22H28FN3O |
Molar mass | 369.484 g·mol−1 |
3D model (JSmol) | |
| |
|
TRV734 is a drug developed by Trevena Inc which acts as a biased agonist at the μ-opioid receptor, selective for activation of the G-protein signalling pathway over β-arrestin 2 recruitment. It is closely related to oliceridine and has a similar pharmacological profile, but unlike oliceridine which has to be injected, TRV734 is suitable to be administered orally.[1]
See also
References
- ^ James IE, Skobieranda F, Soergel DG, Ramos KA, Ruff D, Fossler MJ (February 2020). "A First-in-Human Clinical Study With TRV734, an Orally Bioavailable G-Protein-Biased Ligand at the μ-Opioid Receptor". Clinical Pharmacology in Drug Development. 9 (2): 256–266. doi:10.1002/cpdd.721. PMID 31286645. S2CID 195843184.
Categories:
- Articles with short description
- Short description matches Wikidata
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- All stub articles
- Pharmacology stubs
- Mu-opioid receptor agonists
- Pyridines
- Fluoroarenes
- Spiro compounds
- Oxygen heterocycles
- Amines